<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>tjfmpc</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Turkish Journal of Family Medicine and Primary Care</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">1307-2048</issn>
                                                                                            <publisher>
                    <publisher-name>Aile Hekimliği Akademisi Derneği</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.21763/tjfmpc.1186418</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Primary Health Care</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Birinci Basamak Sağlık Hizmetleri</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <trans-title-group xml:lang="en">
                                    <trans-title>Evaluation of Hepatitis A and Hepatitis C serologies and Hepatitis B vaccine application responses in adolescent children</trans-title>
                                </trans-title-group>
                                                                                                                                                                                                <article-title>Adölesan yaştaki çocuklarda Hepatit A ve Hepatit C serolojileri ile Hepatit B aşı uygulaması yanıtlarının değerlendirilmesi</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-9074-9469</contrib-id>
                                                                <name>
                                    <surname>Mıngır</surname>
                                    <given-names>Serdar</given-names>
                                </name>
                                                                    <aff>14 Nolu Aile Sağlığı Merkezi/ Afyonkarahisar</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-7449-7513</contrib-id>
                                                                <name>
                                    <surname>Şensoy</surname>
                                    <given-names>Nazlı</given-names>
                                </name>
                                                                    <aff>AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ TIP FAKÜLTESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-6186-2494</contrib-id>
                                                                <name>
                                    <surname>Demirtürk</surname>
                                    <given-names>Neşe</given-names>
                                </name>
                                                                    <aff>AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ TIP FAKÜLTESİ</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20230331">
                    <day>03</day>
                    <month>31</month>
                    <year>2023</year>
                </pub-date>
                                        <volume>17</volume>
                                        <issue>1</issue>
                                        <fpage>126</fpage>
                                        <lpage>131</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20221009">
                        <day>10</day>
                        <month>09</month>
                        <year>2022</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20230123">
                        <day>01</day>
                        <month>23</month>
                        <year>2023</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2007, Turkish Journal of Family Medicine and Primary Care</copyright-statement>
                    <copyright-year>2007</copyright-year>
                    <copyright-holder>Turkish Journal of Family Medicine and Primary Care</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="en">
                            <p>Objective: Viral hepatitis infections are considered by World Health Organizationas a serious public health problem. The incidence of Hepatitis B and Hepatitis C infections in our country is less than Hepatitis A infection. The aim of our research was to determine the seroprevalence and efficacy of the hepatitis B vaccine routinely administered at birth in students born in 1999 and 2003, and to evaluate the seroprevalence of hepatitis A and hepatitis C. Methods: A total of 803 students participated in the study, which was conducted as a cross-sectional prevalence research in the 2015-2016 academic year. In the research, a personal information form including questions about the demographic information of the participants and the source of hepatitis B infection was used. A tube of venous blood was taken and HBsAg, anti-HBs, anti-HBc IgG, anti-HAV IgG, and anti-HCV IgG levels were studied. In the analysis of data; SPSS 18.0 program, descriptive statistics, chi-square test were used, p&amp;lt;0.05 was accepted meaningful. Results: Of the 803 students who participated in our research, 56% (n=454) were female and 44% (n=349) were male. It was found that the Anti-HBs seropositivity rate was 90.5% (353/390) in the 17-year-old group and 51.6% (213/413) in the 13-year-old group, the difference between them was significant (p&amp;lt;0.001). In our research, the overall frequency anti-HAV IgG seropositivity was 16.8% (n=135) and the anti-HCV seropositivity was 0.6% (n=5). Conclusion: Consequently, it was showed that there was a high prevalence of anti-HBs seropositivity in the 17 age group. Interms of Hepatitis A infection, the low rate of catching the disease in both the 13 and 17 age groups reveals the necessity of Hepatitis A vaccine in adolescence. The difference between age groups in our region indicates that long-term results of vaccine efficacy need to be followed up.</p></trans-abstract>
                                                                                                                                    <abstract><p>Amaç: Viral hepatit enfeksiyonları Dünya Sağlık Örgütü tarafından ciddi toplum sağlığı sorunu olarak görülmektedir. Hepatit B ve hepatit C enfeksiyonlarının ülkemizde görülme sıklığı hepatit A enfeksiyonuna göre daha azdır. Çalışmamızın amacı, 1999 ve 2003 doğumlu öğrencilerde doğumlarında rutin uygulanmış olan hepatit B aşı seroprevalansının ve etkinliğinin belirlenmesi, ayrıca hepatit A ve hepatit C seroprevalansını değerlendirmektir. Yöntem: Kesitsel prevalans çalışması olarak planlanan araştırmaya, 2015- 2016 eğitim döneminde toplam 803 öğrenci katıldı. Çalışmada, katılımcıların demografik bilgilerinin ve hepatit B infeksiyonu kaynağı ile ilgili soruların yer aldığı kişisel bilgi formu kullanıldı. Bir tüp venöz kan alındı ve hepatit B yüzey antijeni ve antikoru, anti-core antikoru ve anti-HAV IgG ile hepatit C antikor testleri çalışıldı. Verilerin analizinde; SPSS 18.0 programı, tanımlayıcı istatistikler, ki kare testi kullanıldı, p&amp;lt;0.05 anlamlı kabul edildi. Bulgular: Çalışmamıza katılan 803 öğrencinin %56&#039;sı (n=454) kız, %44&#039;ü (n=349) erkekti. Çalışmamızda Anti-HBs seropozitiflik oranı 17 yaş grubunda %90,5 (353/390), 13 yaş grubunda ise %51,6 (213/413) olarak bulundu; aralarındaki fark anlamlıydı (p&amp;lt;0,001). Araştırmamızda anti-HAV IgG seropozitiflik oranı %16,8 (n=135)  ve anti-HCV seropozitiflik oranı ise %0,6 (n=5) olarak belirlendi. Sonuç: Sonuç olarak 17 yaş grubunda yüksek bir anti-HBs seropozitiflik prevalansı olduğu belirlendi. Hepatit A enfeksiyonu açısından bakıldığında ise hem 13 hem de 17 yaş grubunda hastalığa yakalanma oranının düşük olması, ergenlik döneminde Hepatit A aşısının gerekliliğini ortaya koymaktadır. Bölgemizdeki yaş grupları arasındaki fark, aşı etkinliğinin uzun vadeli sonuçlarının takibinin gerekli olduğunu göstermektedir.</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Hepatit A</kwd>
                                                    <kwd>  Hepatit B</kwd>
                                                    <kwd>  Hepatit C</kwd>
                                                    <kwd>  Adölesan</kwd>
                                                    <kwd>  hepatit prevalansı</kwd>
                                            </kwd-group>
                            
                                                <kwd-group xml:lang="en">
                                                    <kwd>Hepatitis A</kwd>
                                                    <kwd>  Hepatitis B</kwd>
                                                    <kwd>  Hepatitis C</kwd>
                                                    <kwd>  Adolescent</kwd>
                                                    <kwd>  hepatitis prevelance</kwd>
                                            </kwd-group>
                                                                                                                                    <funding-group specific-use="FundRef">
                    <award-group>
                                                    <funding-source>
                                <named-content content-type="funder_name">Afyon Kocatepe Üniversitesi Bilimsel Araştırma Projeleri Birimi tarafından desteklenmiştir.</named-content>
                            </funding-source>
                                                                            <award-id>Proje No:16.TUS.08</award-id>
                                            </award-group>
                </funding-group>
                                </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1. World Health Organization. Global Hepatitis Report 2017. Geneva: World Health Organization (WHO); 2017.  
Erişim adresi:https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf.[Erişim tarihi: 01 Eylül 2022].</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2.Türkiye Viral Hepatit Önleme ve Kontrol Programı 2018-2023. https://hsgm.saglik.gov.tr/depo/birimler/Bulasici-hastaliklar-db. Erişim tarihi: 01.08.2022.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3.World Health Organization. Hepatitis A. Erişim adresi:https://www.who.int/news-room/fact-sheets/detail/Hepatitis-a[Erişim tarihi: 01 Eylül 2022].</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4.World Health Organization. Hepatitis B. Erişim adresi:https://www.who.int/news-room/fact-sheets/detail/Hepatitis-b[Erişim tarihi: 01 Eylül 2022].</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5.World Health Organization. Hepatitis C. Erişim adresi:https://www.who.int/news-room/fact-sheets/detail/Hepatitis-c[Erişim tarihi: 01 Eylül 2022].</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6.Yoldaş Ö, Bulut A, Altındiş M. Hepatit A enfeksiyonlarında güncel yaklaşım, Viral Hepatit Dergisi 2012; 18(3): 81-6.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7. Türker K, Balcı E, Batı S, Hasçuhadar M, Savaş E. Hepatit A infeksiyonunun değişen epidemiyolojisi. Türk Mikrobiyol Cem Derg 2011; 41(4):143-48.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8. Çeviker S A, Günal Ö, Kılıç S S, Köksal E, Tahmaz A. Samsun ilinde farklı yaş gruplarında Hepatit A virüsü seroprevalansı. Balıkesir Sağlık Bilimleri Dergisi 2019; 8(2):81-6.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9. Açıkgöz A, Cimrin D, Kızıldağ S, Esen N, Balci P, Sayiner A A. Hepatitis A, B and C seropositivity among first-year health care students in western Turkey: a seroprevalence study. BMC Infect Dis 2020; 20: 529.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10. Özkan H. Epidemiology of chronic Hepatitis B in Turkey. Euroasian Journal of Hepato-gastroenterology, 2018; 8(1): 73-4.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11. Wang Z, Gao Y, Lu W, Jin CD, Zeng Y, Yan L, et al. Long-term persistence in protection and response to a Hepatitis B vaccine booster among adolescents immunized in infancy in the western region on China. Hum Vaccine Immun other 2017;13(4):909-15.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12. Schönberger K, Riedel C, Rückinger S, Mansmann U, Jilg W, Kries R. Determinants of long-term protection after Hepatitis B vaccination in infancy: a meta-analysis. Pediatr Infect Dis 2013; 32:307-13.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13. Mendy M, Peterson I, Hossin S,Peto T, Jobarteh M, Jeng-Barry A, et al. Observational study of vaccine efficacy 24 years after the start of Hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLosOne 2013; 8(3): e58029.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14. Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, et al. Differences in Hepatitis A seroprevalence among geographical regions in Turkey: a need forregional vaccination recommendations. J Viral Hepat. 2008 Oct;15 Suppl 2:69-72.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15. Kanra G, Tezcan S, Badur S. Turkish National Study Team. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr. 2002 Jul-Sep;44(3):204-10.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16. Aşçı Z, Akgün S, Keşli R, Demirtürk N. Afyonkarahisar ilinde farklı yaş gruplarında Hepatit A seroprevalansı. Göztepe Tıp Dergisi 2014; 29(2):94-8.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17. van den Ende C, Marano C, vanAhee A, Bunge EM, De Moerlooze L. The immunogenicity of GSK&#039;s recombinant Hepatitis B vaccine in children: a systematic review of 30 years experience. Exp Rev Vaccine 2017; 16 (8):789-809.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18. Li X, XU Y, Dong Y  Yang X, Ye B, Wang Y, Chen Y, et al. Monitoring the efficacy of infant Hepatitis B vaccination and revaccination in 0-to-8-year old children: protective anti-HBs levels and cellular immune response. Vaccine 2018; 36(18):2442-49.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19. World Health Organization. Global health sector strategy on viral Hepatitis 2016-2021. Toward sending viral hepatitis. 
Erişim adresi: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1. [Erişim tarihi: 01 Eylül 2022].</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20. Chaves S, Fischer G, Groeger J, Patel P R, Thompson N D, Teshale E H, et al. Persistence of long-term immunity to Hepatitis B among adolescents immunized at birth. Vaccine 2012;30 (9):1644-49.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21. Su FH, Cheng SH, Li CY, Chen JD, Hsiao CH, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national Hepatitis B vaccination. Vaccine 2007;25(47):8085-90.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22. Tosun S. Türkiye’de Viral Hepatit B Epidemiyolojisi Yayınlarının Meta Analiz. Tabak F, Balık İ Editörler. Viral Hepatit. Viral Hepatitle Savaşım Derneği Yayını. İstanbul: İstanbul Medikal Yayıncılık; 2013. p.27-80.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23. Tozun N, Ozdogan O, Cakaloğlu Y, Idilman R, Karasu Z, Akarca U ve ark.  Seroprevalence of Hepatitis B and C virüs infections and risk factors in Turkey: A Fieldwork TURHEP Study. Clin Microbiol Infect 2015; 21(11): 1020-26.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24. Doğan E, Sevinç E, Cüneyt K. Karabük İlinde Çocuklarda Hepatit A, B ve C seroprevalansı. Akademik Gastroenteroloji Dergisi 2017;16(3): 97-100.</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">25. Çiçek A Ç, Özkasap S, Dereci S, Şahin K, Gündoğdu D Z U, Dilek A R ve ark. Rize ilinde çocuk hastalarda Hepatit A, B ve C seroprevalansı. Viral Hepat J 2012;18:102-6.</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">26. Duran F, Kaya A, Zararsız A, Şahin İ O, Aldemir B A, Bostancı P K, Cura C. Hastanemize başvuran 0-18 yaş arası çocuklarda Hepatit B, Hepatit C ve Hepatit D seroprevalansı. J Pediatr Inf2017;11:1-6.</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">27.Arshad A,  Ashfaq U A. Epidemiology of hepatitis C infection in Pakistan: current estimate and major risk factors. Crit Rev Eukaryot Gene Expr. 2017;27(1):63-77.</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">28. Eke CB, Ogbodo SO, Ukoha OM. Seroprevalence and correlates of hepatitis c virüs infection in secondary schoolchildren in Enugu, Nigeria. Ann Med Health SciRes2016;6:156-61.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
